US headquartered TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, has announced a distribution agreement with BioServe Biotechnologies India Pvt Limited, a Hyderabad-based subsidiary of REPROCELL.  BioServe will distribute TriLink BioTechnologies products and services in India, Sri Lanka, Bangladesh and Nepal.

TriLink is known throughout the world for synthesizing high-quality nucleic acid products for research, diagnostics and therapeutics applications. These products are used by academic and biopharmaceutical customers working in the fields of gene therapy, nucleoside chemotherapy, oligonucleotide therapy, next-generation sequencing (NGS) and PCR. TriLink also offers state-of-the-art reagents for CRISPR/Cas9 and mRNA synthesis, capping and transcription.

In order to meet the accelerating demand for mRNA clinical-trial-grade material, TriLink is completing a move to a new, larger facility and is expanding its cGMP production suites, which will be fully functional in the first quarter of 2020. The facility is equipped to manufacture and process oligonucleotides, aptamers and nucleoside triphosphates in addition to mRNA and long RNA. This distribution agreement will enable BioServe India to offer Indian researchers and biopharmaceutical companies the services of a leading contract manufacturing organization for GMP mRNA production.

Lalith Kishore, CEO of REPROCELL South Asia, commented, “This agreement will bring world-class nucleic acid synthesis services to India and will accelerate DNA- and RNA-based therapeutics and diagnostics research and biopharmaceutical projects. We look forward to making this partnership work for our customers in academia and biopharmaceutical development.”

“We are very excited to be working with BioServe Biotechnologies, as the company has a strong track record for distribution, sales and customer service to life science researchers in India,” commented Ravi Vinayak, Ph.D., general manager of global channel distribution for Maravai LifeSciences, parent company of TriLink. “We had previously offered our products in India on a very small scale and we are pleased to ramp up our presence with BioServe, as they have excellent coverage for distribution and support. We are now well positioned to meet the rapidly growing needs of the Indian academic and biopharma communities.”

BioServe is celebrating its 25th anniversary this year and is one of the largest nucleic acid synthesis companies in India, offering a wide range of scales and modifications to the research and industrial community.